Dialysis
Baxter lands CE Mark for VIVIA multi-setting hemodialysis system
NxStage Medical gains on Medicare boost
NxStage Medical (NSDQ:NXTM) shares are on the rise this morning after the Centers for Medicare & Medicaid Services announced Friday that it will boost the training rate for home hemodialysis.
NXTM shares were trading at $9.98 apiece as of about 10 a.m. today, up 3.5%.
NxStage debuts 3 new home-dialysis products
NxStage Medical (NSDQ:NXTM) debuted 3 new products this week during the American Society of Nephrology’s Annual Kidney Week 2013.
The Lawrence, Mass-based medical device company trotted out its System One S, the next generation of NxStage’s System One. It features higher dialysate flow rates, allowing for a wider range of flexible therapy options.
B. Braun, DaVita ink supply deal
B. Braun Medical said it’s entered an agreement with DaVita to provide its Dialog+ dialysis equipment to fill a portion of DaVita’s product requirement.
Bethlehem, Pa.-based Braun has been a leader in the dialysis field for years and has a long-standing relationship with DaVita. The Dialog+ system allows patients to have the greatest number of possible configurations for individual treatment.
Legal: Fresenius is off the hook as Baxter fails to recoup $24M infringement decision
NxStage tanks on lowered 2013 guidance amid weak home hemo results
Baxter warns on dialysis device
Wound Management Tech. accepts loans, merges with Brookhaven Medical
Texas-based Wound Management Technologies entered into a merger agreement with Brookhaven Medical, a closed-doors deal tied to a series of loans proffered by Brookhaven.
Medtronic enlists allies to breach India’s dialysis market
NxStage debuts 1st dialysis center
NxStage Medical (NSDQ:NXTM) said its NxStage Kidney Care division opened its 1st dialysis center outside of St. Louis after winning Medicare certification from the Missouri Board of Health.